Dabigatran Etexilate

Dabigatran etexilate is an oral anticoagulant (blood thinner) approved across several products for the following conditions:

• Reducing the risk of stroke and systemic embolism (clots in the bloodstream) in adults with non-valvular atrial fibrillation (irregular heart rhythm not related to a heart valve problem)
• Treating deep venous thrombosis (DVT) — a blood clot in a deep vein — and pulmonary embolism (PE) — a clot in the lungs — in adults, after at least 5–10 days of injectable anticoagulation
• Reducing the risk of DVT and PE coming back in adults who have already been treated
• Preventing DVT and PE in adults after hip replacement surgery
• Pradaxa Capsules: treating VTE and reducing the risk of recurrence in pediatric patients aged 8 to less than 18 years (after at least 5 days of injectable anticoagulation)
• Pradaxa Oral Pellets: treating VTE and reducing the risk of recurrence in pediatric patients aged 3 months to less than 12 years (after at least 5 days of injectable anticoagulation)

Dabigatran etexilate is converted in the body into dabigatran, which directly blocks thrombin — a critical protein that drives blood clot formation. By blocking thrombin, dabigatran prevents fibrinogen from being converted into fibrin, the material that forms clots. It works against both free thrombin in the bloodstream and thrombin already bound within a clot, and it also reduces thrombin-driven platelet clumping.

Dabigatran etexilate capsules are taken by mouth, typically twice daily. They can be taken with or without food — a high-fat meal may slow absorption slightly but does not change the total amount absorbed. Capsules must always be swallowed whole; opening, breaking, or chewing them dramatically increases drug exposure and should never be done.

• Dosing frequency and amount depend on your kidney function, the condition being treated, and any other medications you take — your prescriber will determine the right regimen for you
• For hip replacement surgery, a different dosing schedule applies — follow your prescriber's instructions exactly
• Dabigatran formulations (capsules vs. oral pellets) are not interchangeable on a milligram-for-milligram basis — do not switch forms without medical guidance
• If you miss a dose, follow the guidance on your prescription label and ask your pharmacist if you are unsure

The most common side effects affect the stomach and involve bleeding. Here's what to watch for:

• Gastrointestinal upset: dyspepsia (indigestion), nausea, upper abdominal pain, diarrhea
• Gastritis-like symptoms: heartburn, esophagitis (inflamed esophagus), stomach irritation
• Bleeding — including gastrointestinal bleeding (more common than with warfarin)
• Skin reactions: rash, itching, hives

Serious reactions — including severe bleeding, signs of spinal hematoma (back pain, leg numbness or weakness, bladder/bowel problems), or a severe allergic reaction (swelling, difficulty breathing) — require emergency care right away.

• Bleeding risk: Dabigatran etexilate can cause serious and fatal bleeding. Any unexplained bleeding, blood in urine or stool, or sudden drop in blood pressure warrants immediate evaluation. A reversal agent (idarucizumab) is available for adults in emergencies.
• Do not stop suddenly: Stopping without transitioning to another anticoagulant sharply raises the risk of stroke or dangerous clots. Always talk to your doctor before discontinuing.
• Spinal/epidural hematoma: If you receive spinal or epidural anesthesia or have a spinal puncture, there is a risk of bleeding around the spinal cord that can cause permanent paralysis. Report any back pain, leg numbness, or loss of bladder/bowel control immediately.
• Mechanical prosthetic heart valves: Dabigatran is contraindicated — it caused more clots and bleeding than warfarin in this group in clinical trials.
• Bioprosthetic heart valves or triple-positive antiphospholipid syndrome: Use is not recommended — safety has not been established.
• Kidney function matters: Dabigatran is cleared mainly by the kidneys. Poor kidney function raises drug levels and bleeding risk; dose adjustments or avoidance may be needed.

Dabigatran etexilate interacts with several drugs that affect how much of it enters your bloodstream or that add to its blood-thinning effect:

• P-gp inducers (e.g., rifampin): Lower dabigatran levels in the blood — generally avoid combining, as the drug may not work effectively
• P-gp inhibitors (e.g., dronedarone, systemic ketoconazole): Raise dabigatran levels — may require a dose reduction or should be avoided, especially if you also have kidney problems
• Other P-gp inhibitors (verapamil, amiodarone, quinidine, clarithromycin, ticagrelor): Increase dabigatran exposure but may not require dose changes — your doctor will advise
• Other anticoagulants, heparin, or clot-busting drugs: Significantly raise the risk of bleeding when combined
• NSAIDs (ibuprofen, naproxen) used chronically or anti-platelet drugs (aspirin, clopidogrel): Increase bleeding risk — discuss with your doctor before regular use

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Active abnormal bleeding: Do not take dabigatran etexilate if you have ongoing pathological bleeding
• Mechanical prosthetic heart valve: Contraindicated — do not use
• Serious prior allergic reaction to dabigatran: Do not use if you've had anaphylaxis or anaphylactic shock from this drug
• Kidney disease: Tell your doctor — dosing may need adjustment, and some combinations with other drugs must be avoided
• Triple-positive antiphospholipid syndrome: Use is not recommended
• Bioprosthetic (tissue) heart valve: Use is not recommended — not studied in this group
• Pregnancy: Dabigatran may cause bleeding in the mother, fetus, or newborn; discuss risks carefully with your doctor
• Breastfeeding: Not recommended — it is unknown whether dabigatran passes into human milk
• Older adults (75+): Higher bleeding risk — your doctor will weigh the risks and benefits
• Children under 8: Dabigatran etexilate capsules are not approved for children under 8; age-appropriate formulations (Pradaxa Oral Pellets) exist for younger children
• Planned surgery or spinal procedures: Tell your surgeon and anesthesiologist — dabigatran should typically be paused before procedures, then restarted promptly

Taking too much dabigatran etexilate can cause serious bleeding. If an overdose is suspected, stop the medication, seek emergency medical care, and identify the source of any bleeding. In adults, a specific reversal agent called idarucizumab can rapidly reverse dabigatran's effects. Hemodialysis can also remove a significant portion of dabigatran from the blood, though clinical experience with this approach is limited.

At therapeutic doses, dabigatran etexilate prolongs certain blood-clotting lab tests — including aPTT (activated partial thromboplastin time) and ECT (ecarin clotting time) — which reflect its anticoagulant activity. Unlike warfarin, the standard INR test is not a reliable measure of dabigatran's effect. The drug does not affect the heart's electrical rhythm (no QTc prolongation has been observed).

After you swallow dabigatran etexilate, the body converts it into its active form, dabigatran, through a process called ester hydrolysis. Peak blood levels are reached within about 1 hour on an empty stomach; food can delay this by about 2 hours but doesn't change the total amount absorbed. Dabigatran is mostly eliminated by the kidneys — about 80% of the drug leaves the body in urine — with a half-life (the time for half the drug to clear) of 12 to 17 hours in adults with normal kidney function. Because the kidneys do most of the work, people with kidney disease clear the drug more slowly, which raises drug levels and bleeding risk.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Store in the original package to protect from moisture.